Akebia Therapeutics, Inc. (AKBA) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for standing by. This is Roy, and I will be your conference operator today. At this time, I would like to welcome everyone to the Akebia's second quarter twenty twenty six financial results. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. I would now like to turn the conference over to Mercedes Kraasco. Please go ahead. Thank you, and welcome to Akebia's Second Quarter twenty twenty six Financial Results and Business Updates Conference Call. Please note that a press release was issued earlier today, Wednesday, August 5, detailing our second quarter twenty twenty six financial results, and that release is available on the Investors section of our website. For your convenience, a replay of today's call will also be available on our website after we conclude. Joining me today, we have John Butler, Chief Executive Officer Doctor. Steven Burke, our Chief Medical Officer Nick Grund, our Chief Commercial Officer and Eric Ostrovsky, Chief Financial and Chief Business Officer. I'd like to remind everyone that this call includes forward looking statements. Each forward looking statement on this call is subject to risks and uncertainties that could cause actual results to differ materially from those described in these statements. Additional information describing these risks is included in the financial results press release that we issued on August 5, as well as in the Risk Factors and Management Discussion and Analysis section of our most recent annual and quarterly reports filed with the SEC. With that, I'd like to introduce our CEO, John Butler. Thanks, Mercedes, and thanks to everyone for joining us this afternoon. As you know, we've been focused o...